Corcept Therapeutics Incorporated
NASDAQCorcept Therapeutics heads into the post-earnings week with the sharpest analyst split in months, as a fresh Wolfe Research downgrade collides head-on with a bullish target raise from Canaccord Genuity. The contrast is stark. On Monday, Wolfe Research downgraded CORT to Underperform and slapped a $50 price target on the stock — implying roughly 47% downside from Tuesday's close of…
CORT cost to borrow surges 184% in one week to 0.40%, signaling rising short pressure despite minimal short interest at 8.1% of float.
Snapshot as of 26 Aug 2026
Corcept Therapeutics heads into the post-earnings week with the sharpest analyst split in months, as a fresh Wolfe Research downgrade collides head-on with a bullish target raise from Canaccord Genuity. The contrast is…
Corcept Therapeutics has shifted gear: the stock is up 18% on the week and 38% over the past month, and this time the shorts are finally moving with it. The most meaningful change since last week's note is in short…
Corcept Therapeutics is climbing hard while short sellers refuse to blink — the stock has gained 31% in a month, yet short interest barely budged. Options traders have flipped from defensive to outright bullish in a…
Corcept Therapeutics enters the week after a strong earnings beat with shorts beating a steady retreat — and a high-profile analyst upgrade arriving just as the stock consolidates those gains. The setup is a study in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CORT — free to start on ORTEX.
Sign up for free →Open CORT on ORTEX